# Armata Pharmaceuticals, Inc.: overview

ARMP · NYSE · CIK 921114 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/armp.md) · [Financials](/companies/armp/financials.md) · [Filings](/companies/armp/filings.md) · [Insiders](/companies/armp/insiders.md)

Latest reported revenue: [$31.0k](/filings/0001558370-20-010541.md) for Q2 FY2020, three months to 2020-06-30, from the 10-Q filed Aug 13, 2020 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001558370-20-010541).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.15)](/filings/0001104659-25-110383.md) | not reported | [(0.20)](/filings/0001104659-26-060333.md) | [(0.45)](/filings/0001104659-26-094907.md) | [(0.74)](/filings/0001104659-25-110383.md) | not reported | [(3.16)](/filings/0001104659-26-060333.md) | [(0.27)](/filings/0001104659-26-094907.md) |
| Free cash flow | $k | [(9,203) d](/filings/0001104659-25-110383.md) | [(8,004) d](/filings/0001104659-26-034532.md) | [(7,679)](/filings/0001104659-26-060333.md) | [(7,360) d](/filings/0001104659-26-094907.md) | [(4,540) d](/filings/0001104659-25-110383.md) | [(6,726) d](/filings/0001104659-26-034532.md) | [(5,845)](/filings/0001104659-26-060333.md) | [(8,683) d](/filings/0001104659-26-094907.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.96)](/filings/0001558370-23-004014.md) | [(1.08)](/filings/0001558370-24-003706.md) | [(1.91)](/filings/0001558370-25-003406.md) | [(0.89)](/filings/0001104659-26-034532.md) | [(4.80)](/filings/0001104659-26-034532.md) |
| Free cash flow | $m | [(24.9)](/filings/0001558370-23-004014.md) | [(34.7)](/filings/0001558370-24-003706.md) | [(55.6)](/filings/0001558370-25-003406.md) | [(39.4)](/filings/0001104659-26-034532.md) | [(26.3)](/filings/0001104659-26-034532.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/armp/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2022-03-31 | [Innoviva, Inc.](/insiders/1080014.md) | Director, 10% owner | Purchase (P) | 5,385,208 | $5.00 | $26.9m | [Form 4](/filings/0001567619-22-007861.md) |
| 2022-02-09 | [Innoviva, Inc.](/insiders/1080014.md) | Director, 10% owner | Purchase (P) | 3,614,792 | $5.00 | $18.1m | [Form 4](/filings/0001567619-22-003750.md) |
| 2021-10-29 | [Innoviva, Inc.](/insiders/1080014.md) | Director, 10% owner | Purchase (P) | 1,212,122 | $3.30 | $4.0m | [Form 4](/filings/0001567619-21-019063.md) |
| 2021-03-17 | [Innoviva, Inc.](/insiders/1080014.md) | Director, 10% owner | Purchase (P) | 4,285,935 | $3.25 | $13.9m | [Form 4](/filings/0001567619-21-006518.md) |
| 2021-01-26 | [Innoviva, Inc.](/insiders/1080014.md) | Director, 10% owner | Purchase (P) | 1,867,912 | $3.25 | $6.1m | [Form 4](/filings/0000899243-21-003595.md) |
| 2020-03-27 | [Innoviva, Inc.](/insiders/1080014.md) | 10% owner | Purchase (P) | 7,717,661 | $2.87 | $22.1m | [Form 4](/filings/0001567619-20-007226.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Madison Asset Management, LLC](/funds/1299351.md) | 2026-06-30 | $13.7m | 2,107,175 |  | Reduced −500 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $3.6m | 559,986 |  | Added +494,936 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $3.2m | 487,968 |  | Added +121,940 |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $3.0m | 470,500 |  | Added +212,508 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.8m | 270,550 |  | Added +155,995 |
| [Dauntless Investment Group, LLC](/funds/2044285.md) | 2026-06-30 | $1.3m | 203,891 |  | Added +113,311 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $839.8k | 129,600 |  | Added +78,800 |
| [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $581.8k | 89,791 |  | Added +65,145 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $527.2k | 81,354 |  | New +81,354 |
| [EDGEWOOD MANAGEMENT LLC](/funds/860561.md) | 2026-06-30 | $518.4k | 80,000 |  | Reduced −20,000 |

## Recent filings

[All 756 filings](/companies/armp/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-23 | 07:10 ET | [8-K](/filings/0001104659-26-109809.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-109809 |
| 2026-09-14 | 07:12 ET | [8-K](/filings/0001104659-26-107253.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-107253 |
| 2026-08-12 | 16:23 ET | [10-Q](/filings/0001104659-26-094907.md) | Quarterly report, period 2026-06-30 | 0001104659-26-094907 |
| 2026-08-12 | 16:16 ET | [8-K](/filings/0001104659-26-094896.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-094896 |
| 2026-07-20 | 07:13 ET | [8-K](/filings/0001104659-26-084861.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-084861 |
| 2026-07-20 | 07:12 ET | [8-K](/filings/0001104659-26-084860.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-26-084860 |
| 2026-07-13 | 07:11 ET | [8-K](/filings/0001104659-26-082850.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-082850 |
| 2026-06-24 | 16:19 ET | [8-K/A](/filings/0001104659-26-077313.md) | 5.02 Departure or appointment of officers or directors | 0001104659-26-077313 |
| 2026-06-23 | 07:10 ET | [8-K](/filings/0001104659-26-076627.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-076627 |
| 2026-06-16 | 16:43 ET | [8-K](/filings/0001104659-26-074618.md) | 5.07 Shareholder vote results | 0001104659-26-074618 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-034532.md), filed Mar 25, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 921114
- Tickers: ARMP
- Exchange: NYSE
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: WA
- Filer category: Non-accelerated filer<br>Smaller reporting company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:28 ET. No prices; not investment advice.